Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis | Zendy

Hugo C. Turner | Zendy; Alison A. Bettis | Zendy; Brian Chu | Zendy; Deborah A. McFarland | Zendy; Pamela J. Hooper | Zendy; Sunny Mante | Zendy; Christopher Fitzpatrick | Zendy; Mark Bradley | Zendy

Open Access

Investment success in public health: An analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis

Author(s) -

Hugo C. Turner,

Alison A. Bettis,

Brian Chu,

Deborah A. McFarland,

Pamela J. Hooper,

Sunny Mante,

Christopher Fitzpatrick,

Mark Bradley

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw835

Subject(s) - lymphatic filariasis , cost effectiveness , medicine , cost–benefit analysis , hydrocele , public health , economic cost , value of life , environmental health , filariasis , risk analysis (engineering) , surgery , economics , ecology , nursing , neoclassical economics , biology , helminths , immunology , microeconomics

It has been estimated that $154 million per year will be required during 2015-2020 to continue the Global Programme to Eliminate Lymphatic Filariasis (GPELF). In light of this, it is important to understand the program's current value. Here, we evaluate the cost-effectiveness and cost-benefit of the preventive chemotherapy that was provided under the GPELF between 2000 and 2014. In addition, we also investigate the potential cost-effectiveness of hydrocele surgery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research